Development of T cell receptor repertoires during childhood in health and disease
By Emma A., Bunia A., Othilia FS., Tobias C. & Joanna R.
Group 21
Introduction
Data Description
Materials: What data did you use and where did you get it from? Methods: Which modelling did you use? Think of the methods section as a recipe for how to go from raw to results => Flow chart? Discuss how data was collected or generated for your study. Include any relevant details or procedures.
# A tibble: 6 × 2 sample_name sample_tags <chr> <chr> 1 310183_TCRB 06 Years, 6 Years at visit, Caucasian, Control, Control 022, GAD6…2 310110_TCRB 0 Years at visit, 09 Months, 6.37808219178082 Years at diagnosis,…3 310206_TCRB 0 Years at visit, 10 Months, 10.558904109589 Years at diagnosis, …4 310288_TCRB 09 Years, 9 Years at visit, 9.56986301369863 Years at diagnosis, …5 310271_TCRB 02 Years, 2 Years at visit, 6.87397260273973 Years at diagnosis, …6 310244_TCRB 05 Years, 18.0438356164384 Years at diagnosis, 5 Years at visit, …
>>>>>>> 5e07d0beedcc9d6012b399969affd60dc9d32a55
Right column
Antibody Expression
Antibody Expression, PCA
HLA Expression
<<<<<<< HEAD
=======
>>>>>>> 5e07d0beedcc9d6012b399969affd60dc9d32a55
HLA Expression, PCA
Discussion
Discuss the implications of your findings. Interpret the results and relate them to your objectives.
<<<<<<< HEAD - ZnT8 for control patients … - Missing values for control patients - Missing data for control makes it difficult to determine significant differences between antibody expression for case and control - Results from PCA seems to suggest reducing dimensionality of data by clustering antibodies - No dimensionality reduction suggested from PCA on HLA
Conclusion
Summarize the main points discussed in the presentation. Emphasize the significance of your work and any future directions.